Current issues in delivering DCs for immunotherapy

References

• Sallusto F', Schaerli P, Loetscher P et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur y Immunol 1998;28:2760–9.
   Google Scholar
• De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12–7.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. 7 Exp Med 2001;193: 233–8.
   Google Scholar
• Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8( ) regulatory T cells in vivo in humans. Blood 2002;100:174— 7.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Sapp M et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. 7 Clin Invest 1999;104:173— 80.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Krasovsky J, Steinman RM et al. Mature dendritic cells boost functionally superior CD8( ) T-cell in humans without foreign helper epitopes. 7 Clin Invest 2000;105:R9— R14.
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int y Cancer 2001;93:243— 51.
   PubMed Web of Science ®Google Scholar
• McIlroy D, Gregoire M. Optimizing dendritic cell-based antic-ancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 2003;published online June 24:1— 18.
   Google Scholar
• Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced Stage W melanoma. 7 Exp Med 1999;190:1669— 78.
   PubMed Web of Science ®Google Scholar
• Schuler-Thurner B, Dieckmann D, Keikavoussi P et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1melanoma patientsby mature monocyte-derived dendritic cells. 7 Immunol 2000;165: 3492 — 6.
   Google Scholar
• O'Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003;52:387— 95.
   Google Scholar
• de Vries 1J, Eggert AA, Scharenborg NM et al. Phenotypical and functional characterization of clinical grade dendritic cells. 7 Immunother 2002;25: 429— 38.
   Google Scholar
• Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol Immunother 2002;51:637–44.
   PubMed Web of Science ®Google Scholar
• Lin CL, Lo WF, Lee TH et al. Immunization with Epstein— BarrVirus (EBV) peptide-pulsed dendritic cells induces functional CD8± T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002;62:6952— 8.
   PubMed Web of Science ®Google Scholar
• Stift A, Friedl J, Dubsky P et al. Dendritic cell-based vaccinationin solid cancer. y Gun Oncol 2003;21:135–42.
   PubMed Web of Science ®Google Scholar
• Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. y Exp Med 2002;195:1279— 88.
   PubMed Web of Science ®Google Scholar
• Hold L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002;8:3369— 76.
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokinesand prostaglandins induce maturation of potent immunostimu-latory dendritic cells under fetal calf serum-free conditions. Eur y Immunol 1997;27:3135–42.
   PubMed Web of Science ®Google Scholar
• Scandella E, Men Y, Gillessen S et al. Prostaglandin E2 is a keyfactor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002;100:1354— 61.
   PubMed Web of Science ®Google Scholar
• Luft T, Jefford M, Luetjens P et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 2002;100:1362— 72.
   PubMed Web of Science ®Google Scholar
• Kalinski P, Vieira PL, Schuitemaker JH et al. Prostaglandin E(2)is a selective inducer of interleukin-12 p40 (IL-12p40) produc-tion and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001;97:3466— 9.
   PubMed Web of Science ®Google Scholar
• Kalinski P, Schuitemaker JH, Hilkens CM et al. Final maturationof dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. y Immunol 1999;162:3231–6.
   Google Scholar
• Langenkamp A, Messi M, Lanzavecchia A et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000;1:311–6.
   PubMed Web of Science ®Google Scholar
• Vieira PL, de Jong EC, Wierenga EA et al. Development of Thl-inducing capacity in myeloid dendritic cells requires environ-mental instruction. y Immunol 2000;164:4507–12.
   Google Scholar
• Spisek R, Bougras G, Ebstein F et al. Transient exposure of dendritic cells to maturation stimuli is sufficient to induce complete phenotypic maturation while preserving dendritic cell capacity to respond to subsequent restimulation. Cancer Immunol Immunother 2003;52:445— 54.
   PubMed Web of Science ®Google Scholar
• Oldenhove G, de Heusch M, Urbain-Vansanten G et al. CD4±CD25± regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. y Exp Med 2003;198:259–66.
   PubMed Web of Science ®Google Scholar
• Eggert AA, Schreurs MW, Boerman OC et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340–5.
   PubMed Web of Science ®Google Scholar
• Morse MA, Coleman RE, Akabani G et al. Migration of humandendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56— 8.
   PubMed Web of Science ®Google Scholar
• Mackensen A, Krause T, Blum U et al. Homing of intravenouslyand intralymphatically injected human dendritic cells generated in vitro from CD34± hematopoietic progenitor cells. Cancer Immunol Immunother 1999;48:118— 22.
   PubMed Web of Science ®Google Scholar
• Barratt-Boyes SM, Zimmer MI, Harshyne LA et al. Maturationand trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. y Immunol 2000;164:2487— 95.
   Google Scholar
• Barratt-Boyes SM, Watkins SC, Finn 0J. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. y Immunol 1997;158: 4543— 7.
   Google Scholar
• Gunzer M, Friedl P, Niggemann B et al. Migration of dendritic cells within 3-D collagen lattices is dependent on tissue origin, state of maturation, and matrix structure and is maintained by proinflammatory cytokines. 7 Leukoc Biol 2000;67:622— 9.
   PubMed Web of Science ®Google Scholar
• Ratzinger G, Stoitzner P, Ebner S et al. Matrix metalloprotei-nases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. y Immunol 2002;168:4361— 71.
   Google Scholar
• Gilliet M, Kleinhans M, Lantelme E et al. Intranodal injection ofsemimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood 2003;102:36–42.
   PubMed Web of Science ®Google Scholar
• Maier T, Tun-Kyi A, Tassis A et al. Vaccination of patients withcutaneous T cell lymphoma using intranodal injection of autologous tumor lysate pulsed dendritic cells, Blood 2003:102;2338–44.
   Google Scholar
• Kukutsch NA, Rossner S, Austyn JM et al. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. y Invest Dermatol 2000;115:449 — 53.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanomapatients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328–32.
   PubMed Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C et al. Dendritic cells injected viadifferent routes induce immunity in cancer patients. y Immunol 2001;166:4254— 9.
   Google Scholar
• Brown K, Gao W, Alber S et al. Adenovirus-transduced DCs injected into skin or lymph node prime potent simian im-munodeficiency virus-specific T cell immunity in monkeys. 7 Immunol 2003;171: 6875— 82.
   Google Scholar
• Fong L, Brockstedt D, Benike C et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. Immunol 2001;167:7150–6.
   Web of Science ®Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34( ) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451–8.
   PubMed Web of Science ®Google Scholar
• Smithers M, O'Connell K, MacFadyen S et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 2003;52:41–52.
   Google Scholar
• Esslinger C, Chapatte L, Finke D et al. In vivo administration ofa lentiviral vaccine targets DCs and induces efficient CD8( ) T cell responses. 7 Clin Invest 2003;111:1673–81.
   PubMed Web of Science ®Google Scholar